FDA lenacapavir coverage for business development, investment, and market access teams
Merck and Gilead report mixed outcomes in lung cancer and HIV studies
Lenacapavir posts 100% HIV prevention in PURPOSE 1
Lenacapavir PrEP shows high HIV-prevention efficacy in Gilead’s Phase 3 trials
HIV Treatment Clinical Trials Africa: Long-Acting Injectables & AMA Pathways
FDA Grants Priority Review for Gilead's Bictegravir Plus Lenacapavir HIV Treatment Combination
SAHPRA HIV treatment approval: Lenacapavir's Role in Epidemic Control
SAHPRA Approval of Lenacapavir: A New Era in HIV Prevention in South Africa
FDA Approves Gilead's Long-Acting HIV Treatment for Bi-Monthly Dosing